Slide Source: Lipids Online Slide Library www.lipidsonline.org HMG-CoA Reductase Inhibitor: Secondary Prevention Baseline LDL-C (mg/dL) Statin (n = 10
{"Image DocumentName": "Heart Protection Study (HPS) Baseline LDL-C (mg/dL)", "Image ImageDescription": "HMG-CoA Reductase Inhibitor: Secondary Prevention. Heart Protection Study (HPS) 20,536 patients with CAD, other occlusive arterial disease, or DM randomized to simvastatin (40 mg) or placebo for 5.5 years. Baseline LDL-C (mg/dL) Statin (n = 10,269) Placebo (n = 10,267) Event Rate Ratio (95% CI) < (16.4%) 358 (21.0%) 100 \u2013 (18.9%) 871 (24.7%) > (21.6%) 1356 (26.9%) All patients (19.8%) 2585 (25.2%) HMG-CoA reductase inhibitor: secondary prevention. The Heart Protection Study (HPS) sought to evaluate the effect of simvastatin on all-cause mortality in high risk patients regardless of low-density lipoprotein cholesterol (LDL-C) levels. Treatment with simvastatin resulted in a 12% relative risk reduction in all-cause mortality and a 24% relative risk reduction in the first occurrence of any major vascular event. The benefit of simvastatin extended even to individuals with a baseline LDL-C level <100 mg/dL. Reference: Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360: ( ) P< Better. Worse. Statin. CAD=Coronary artery disease, CI=Confidence interval, DM=Diabetes mellitus. HPS Collaborative Group. Lancet 2002;360:7\u201322.", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}